Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists?

Doggrell, Sheila (2015) Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists? Expert Opinion on Drug Safety, 14(6), pp. 801-805.

View at publisher

Abstract

Several new medicines are in development for the treatment of type 2 diabetes, and cardiovascular outcome trials are the gold standard for these medicines. This editorial demonstrates that despite being available for over 10 years, there are no cardiovascular outcome studies for any of the glucagon-like peptide-1 (GLP-1) receptor agonists, which demonstrate cardiovascular safety or benefit in subjects with high cardiovascular risk. The author argues that the FDA should be ensuring that clinical outcome studies for subjects with type 2 diabetes and high cardiovascular risk be undertaken in a timelier manner.

Impact and interest:

1 citations in Scopus
Search Google Scholar™
1 citations in Web of Science®

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

Full-text downloads:

14 since deposited on 06 Oct 2015
11 in the past twelve months

Full-text downloads displays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.

ID Code: 88033
Item Type: Journal Article
Refereed: Yes
Keywords: GLP-1 receptor agonists, cardiovascular safety, cardiovascular outcomes, clinical trials, type 2 diabetes
DOI: 10.1517/14740338.2015.1034106
ISSN: 1744-764X
Subjects: Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > PHARMACOLOGY AND PHARMACEUTICAL SCIENCES (111500)
Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > PHARMACOLOGY AND PHARMACEUTICAL SCIENCES (111500) > Clinical Pharmacology and Therapeutics (111502)
Divisions: Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Copyright Owner: © 2015 Informa UK, Ltd
Deposited On: 06 Oct 2015 01:19
Last Modified: 24 Apr 2016 16:49

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page